about
Current management of vitreous hemorrhage due to proliferative diabetic retinopathyCurrent treatment of toxoplasma retinochoroiditis: an evidence-based review.Bacillus cereus endophthalmitis following intravitreous bevacizumab injection.Refractive outcomes of lens-sparing vitrectomy for retinopathy of prematurity.LASER demarcation photocoagulation for rhegmatogenous retinal detachments.Evaluating retinal toxicity of intravitreal caspofungin in the mouse eye.Gamma knife radiosurgery in neuro-ophthalmology.Evidence for and against intravitreous corticosteroids in addition to intravitreous antibiotics for acute endophthalmitis.Retinal pigment epithelial tears and the management of exudative age-related macular degeneration.Ocriplasmin and its role in the management of vitreoretinal interface disorders.Vitrectomy with and without scleral buckling for retinal detachment repair in pseudophakic patients.Outcomes of vitrectomy for tractional retinal detachment in diabetic retinopathy.Adjunct Intravitreous Triamcinolone Acetonide in the Treatment of Diabetic Macular Edema with Anti-VEGF AgentsPersistent photopsia following course of oral voriconazole.Advances in retinal therapeutics.Incidence and outcomes of uveitis in juvenile rheumatoid arthritis, a synthesis of the literature.Orbital myositis associated with Borrelia burgdorferi (Lyme disease) infection.25-gauge vitrectomy using sulfur hexafluoride and no prone positioning for repair of macular holes.Subepidermal calcified nodules.Ocular toxicity of intravitreous adalimumab (Humira) in the rabbit.Iris-sutured intraocular lenses for ectopia lentis in children.Safety and pharmokinetics of triamcinolone hexacetonide in rabbit eyes.Acute severe visual loss and a brainstem mass.Comment on the publication "Vehicle of triamcinolone acetonide is associated with retinal toxicity and transient increase in lens density" by W. Kai et al.Central retinal vein occlusion with bilateral stenosis of the internal carotid arteries.Invasive conjunctival squamous cell carcinoma presenting with serous retinal detachment.Long-term Retinal Toxicity of Intravitreal Commercially Available Preserved Triamcinolone Acetonide (Kenalog) in Rabbit EyesShort-term Course of Intraocular Pressure after Intravitreal Injection of Triamcinolone AcetonideToxicity of High-Dose Intravitreal Adalimumab (Humira) in the RabbitEffects of intravitreous injection of preserved and non-preserved triamcinolone in rabbit retinaRetinal pigment epithelium tears following ranibizumab for exudative age-related macular degenerationOcular manifestations of juvenile rheumatoid arthritis in Olmsted County, Minnesota: a population-based studyRegression of serous macular detachment due to peripheral exudative hemorrhagic chorioretinopathy following intravitreal bevacizumabLong-term visual outcomes following lens-sparing vitrectomy for retinopathy of prematurityPhotodynamic therapy for bilateral subfoveal choroidal neovascularization complicating stargardt macular dystrophyLong-term observation of exposed scleral exoplant without topical antibiotic prophylaxisIntraoperative breakage of a disposable 23-gauge trocar tipEtanercept monotherapy induces complete resolution of cystoid macular edema in a patient with intermediate uveitisChorioretinitis and panuveitis in an infant with systemic langerhans cell histiocytosisVitreoretinal surgery. Preface
P50
Q26827302-85EC41DB-A973-4610-BB2C-2CAC556865EBQ27693856-803EE634-FA17-412B-B22B-73782B6AE28DQ33330664-FF30012F-4A97-42D4-B5A9-D0C12254FBC6Q33631035-EA752707-1ABE-47C7-8060-929DCD34F1DEQ33694326-BF0AD38A-6A96-4834-B4A7-E9A22F882799Q34101326-C4A6AB6A-77E8-4350-A9A5-06F43500A491Q35582780-24580CDA-C828-4250-855C-D87DE494A1F2Q37706964-C467254C-0F96-4AAF-B2AB-AE18907B9BBBQ37879158-361EDA4B-E332-4C77-BF53-9EBC9A827610Q38194800-8C78934E-182C-4CE8-A448-F91B817845F0Q38194804-FF9883FB-121E-4CBA-B853-A5D6FA78A3BAQ38194807-A118A06D-B563-4123-BD6D-0F5D0D0C8C34Q41998002-EE7473CD-E0FB-4B31-83F5-430A56D96FBBQ42960967-F42DF9C1-23E9-49F5-BA14-FE62CCFF001CQ43160879-7B48C51A-343D-4E57-8974-26A97B35D040Q43838933-710B22B4-336C-44D1-844F-90E22A07291FQ44879368-197D22AB-0EF2-4FAD-BD80-61425B730029Q46017209-BA2658A2-56E8-4EB3-9ADF-87AC8790FE02Q46245917-B752B8B1-780F-4028-88F5-E987AA4FFF43Q46642586-446EFB61-36B4-4368-8E97-593471730BC7Q46686256-8FAA21CC-09A4-43E8-BD6A-5105E8E70121Q46691195-FCEB3659-24CA-40E7-9B69-DBA8DD58D572Q48292435-B0FB6402-78B3-4795-B57F-48AD896D2DCEQ48684890-4F4E5879-322F-40F7-994A-2C7D0D0E0914Q53583121-7106BC18-102D-42A7-AE8F-59CAE15C194DQ54477933-73E544E7-04DF-414B-AECE-F5CB8BE7DE75Q56780398-4CE3745D-687A-4380-BF21-33AD25A865E4Q56780407-468CF589-7825-4B93-BA38-A4B4DD858FCAQ61635512-E38DB3B1-E48B-4E4F-AC69-DE1AC156EA64Q79354767-BC2F034B-759C-4652-87DC-A9EBBD6EB3E7Q79817470-407E124E-EE48-4655-9ED6-EB03DE6D357FQ80587547-3C2B808D-14BB-4325-B951-DEADE88A9074Q83220137-46F1126E-B3F0-4DF2-9462-E06168668952Q84872796-DC523D2B-91B8-4B2F-A555-F5CD9FEE7D0AQ85947123-E34219C0-2DCC-48C8-965B-1956C077532AQ85947252-B5C79AB4-75FC-4271-9850-FC195F9713D5Q85948961-0CC3A030-E956-4175-8E93-440CBF2C0FA8Q85949893-3F4473BF-9CE1-4837-A904-C55F3E90F893Q85950049-F37ADB32-EE80-4D02-9564-1AC051C84677Q87419705-47528DAA-AF11-46E9-ADE3-3687AC73F252
P50
description
hulumtues
@sq
onderzoeker
@nl
researcher
@en
հետազոտող
@hy
name
Petros E. Carvounis
@ast
Petros E. Carvounis
@en
Petros E. Carvounis
@es
Petros E. Carvounis
@nl
Petros E. Carvounis
@sl
type
label
Petros E. Carvounis
@ast
Petros E. Carvounis
@en
Petros E. Carvounis
@es
Petros E. Carvounis
@nl
Petros E. Carvounis
@sl
prefLabel
Petros E. Carvounis
@ast
Petros E. Carvounis
@en
Petros E. Carvounis
@es
Petros E. Carvounis
@nl
Petros E. Carvounis
@sl
P106
P1153
12806147200
P21
P31
P496
0000-0002-3879-3486